Free Trial

Ionis Pharmaceuticals (IONS) Competitors

Ionis Pharmaceuticals logo
$70.86 -0.64 (-0.90%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$70.92 +0.06 (+0.08%)
As of 10/24/2025 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

IONS vs. BIIB, UTHR, INCY, NBIX, EXAS, EXEL, BMRN, MDGL, RGEN, and HALO

Should you be buying Ionis Pharmaceuticals stock or one of its competitors? The main competitors of Ionis Pharmaceuticals include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Exact Sciences (EXAS), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Madrigal Pharmaceuticals (MDGL), Repligen (RGEN), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry.

Ionis Pharmaceuticals vs. Its Competitors

Biogen (NASDAQ:BIIB) and Ionis Pharmaceuticals (NASDAQ:IONS) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Biogen presently has a consensus target price of $180.69, suggesting a potential upside of 20.55%. Ionis Pharmaceuticals has a consensus target price of $78.50, suggesting a potential upside of 10.78%. Given Biogen's higher probable upside, analysts plainly believe Biogen is more favorable than Ionis Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Biogen
0 Sell rating(s)
20 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.35
Ionis Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
15 Buy rating(s)
1 Strong Buy rating(s)
2.80

Biogen has a beta of 0.13, suggesting that its share price is 87% less volatile than the S&P 500. Comparatively, Ionis Pharmaceuticals has a beta of 0.33, suggesting that its share price is 67% less volatile than the S&P 500.

In the previous week, Biogen had 40 more articles in the media than Ionis Pharmaceuticals. MarketBeat recorded 45 mentions for Biogen and 5 mentions for Ionis Pharmaceuticals. Ionis Pharmaceuticals' average media sentiment score of 1.37 beat Biogen's score of 1.04 indicating that Ionis Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Biogen
23 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive
Ionis Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

87.9% of Biogen shares are owned by institutional investors. Comparatively, 93.9% of Ionis Pharmaceuticals shares are owned by institutional investors. 0.2% of Biogen shares are owned by insiders. Comparatively, 2.6% of Ionis Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Biogen has a net margin of 15.31% compared to Ionis Pharmaceuticals' net margin of -28.25%. Biogen's return on equity of 13.85% beat Ionis Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Biogen15.31% 13.85% 8.32%
Ionis Pharmaceuticals -28.25%-45.29%-8.99%

Biogen has higher revenue and earnings than Ionis Pharmaceuticals. Ionis Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Biogen$10.00B2.20$1.63B$10.4614.33
Ionis Pharmaceuticals$705M16.02-$453.90M-$1.84-38.51

Summary

Biogen beats Ionis Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

Get Ionis Pharmaceuticals News Delivered to You Automatically

Sign up to receive the latest news and ratings for IONS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IONS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

IONS vs. The Competition

MetricIonis PharmaceuticalsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$11.40B$2.97B$6.23B$10.66B
Dividend YieldN/A57.75%5.71%4.82%
P/E Ratio-38.5125.2430.2030.21
Price / Sales16.02782.34590.34132.63
Price / CashN/A168.3237.0161.44
Price / Book19.005.6512.046.60
Net Income-$453.90M$33.06M$3.32B$276.82M
7 Day Performance-3.05%3.15%1.89%2.58%
1 Month Performance12.53%8.13%7.68%3.76%
1 Year Performance80.81%-2.49%56.01%33.84%

Ionis Pharmaceuticals Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
IONS
Ionis Pharmaceuticals
3.4994 of 5 stars
$70.86
-0.9%
$78.50
+10.8%
+82.8%$11.40B$705M-38.511,069Upcoming Earnings
BIIB
Biogen
4.7197 of 5 stars
$144.69
-1.3%
$180.15
+24.5%
-18.5%$21.49B$9.68B9.157,605Trending News
Upcoming Earnings
Analyst Upgrade
Analyst Revision
UTHR
United Therapeutics
4.8441 of 5 stars
$440.06
+0.0%
$457.21
+3.9%
+19.5%$19.85B$2.88B17.171,305Positive News
Upcoming Earnings
Analyst Forecast
Insider Trade
INCY
Incyte
4.5535 of 5 stars
$84.73
+1.1%
$84.79
+0.1%
+39.9%$16.36B$4.24B20.852,617Upcoming Earnings
NBIX
Neurocrine Biosciences
4.3993 of 5 stars
$137.35
+0.5%
$163.44
+19.0%
+24.7%$13.55B$2.36B40.421,800Upcoming Earnings
Analyst Forecast
EXAS
Exact Sciences
4.5142 of 5 stars
$59.36
+1.7%
$69.19
+16.6%
-8.0%$11.04B$2.76B0.007,000Analyst Forecast
EXEL
Exelixis
4.7601 of 5 stars
$38.44
+0.8%
$44.42
+15.6%
+37.7%$10.27B$2.17B18.521,147Analyst Upgrade
Analyst Revision
BMRN
BioMarin Pharmaceutical
4.9722 of 5 stars
$52.45
+0.2%
$93.26
+77.8%
-22.6%$10.05B$2.85B14.183,040News Coverage
Analyst Forecast
MDGL
Madrigal Pharmaceuticals
4.8415 of 5 stars
$427.73
-0.4%
$525.88
+22.9%
+107.6%$9.54B$180.13M0.0090Positive News
RGEN
Repligen
4.1887 of 5 stars
$148.67
+2.4%
$169.62
+14.1%
+23.0%$8.17B$634.44M89.101,778
HALO
Halozyme Therapeutics
4.857 of 5 stars
$65.33
+1.9%
$70.44
+7.8%
+34.2%$7.50B$1.02B13.19390Analyst Forecast

Related Companies and Tools


This page (NASDAQ:IONS) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners